Affiliation:
1. Central Medical Laboratories, 6800 Feldkirch, Austria
2. Private University in the Principality of Liechtenstein, 9495 Triesen, Liechtenstein
Abstract
Since the onset of the COVID-19 pandemic in March 2020, over 769 million confirmed COVID-19 cases, including close to 7 million COVID-19-related deaths, have been reported. Although mortality rates have dropped notably compared to the first months of the pandemic, spikes in reported cases and mortality rates continue to be registered. Both recent spikes in case numbers and the continued emergence of new variants suggest that vulnerable patient groups, including older adults, immunocompromised patients, and patients with severe comorbidities, are going to continue to be affected by COVID-19. In order to curb the pandemic, relieve the pressure on primary care facilities, and reduce mortality rates, global vaccination programs have been established by the WHO, with over 13.5 billion vaccine doses having been administered globally. In most immunocompetent individuals, vaccination against COVID-19 results in the production of anti-SARS-CoV-2 spike antibodies. However, certain patient subsets have inadequate or reduced immune responses, and immune responses are known to decrease with age. General recommendations on the timing of booster vaccinations may therefore be insufficient to protect vulnerable patients. This review aims to evaluate the clinical role of anti-SARS-CoV-2 antibodies, focusing on measurement indications, prognostic value, and potential as a correlate of protection to guide future booster vaccination strategies.
Reference92 articles.
1. World Health Organization (2023, July 18). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/.
2. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: Prospective cohort study;Petrilli;BMJ,2020
3. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study;Nyberg;Lancet,2022
4. Centers for Disease Control and Prevention (2023, July 18). Deaths by Select Demographic and Geographic Characteristics: Provisional Death Counts for COVID-19, Available online: https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm.
5. Age-stratified infection fatality rate of COVID-19 in the non-elderly population;Pezzullo;Environ. Res.,2023